Tags

Type your tag names separated by a space and hit enter

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Mil Med Res. 2020 03 13; 7(1):11.MM

Abstract

An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.

Authors+Show Affiliations

Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Zhuhai, 519000, Guangdong, China.Department of Cardiothoracic Surgery, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.Center of Infectious Disease, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China.Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Zhuhai, 519000, Guangdong, China.Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Zhuhai, 519000, Guangdong, China.Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Zhuhai, 519000, Guangdong, China.Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, 119228, Singapore.Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, 119228, Singapore. entwdy@nus.edu.sg.Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, Zhuhai, 519000, Guangdong, China. yanyan35@mail.sysu.edu.cn. Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China. yanyan35@mail.sysu.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32169119

Citation

Guo, Yan-Rong, et al. "The Origin, Transmission and Clinical Therapies On Coronavirus Disease 2019 (COVID-19) Outbreak - an Update On the Status." Military Medical Research, vol. 7, no. 1, 2020, p. 11.
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan, K. S., Wang, D. Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Medical Research, 7(1), 11. https://doi.org/10.1186/s40779-020-00240-0
Guo YR, et al. The Origin, Transmission and Clinical Therapies On Coronavirus Disease 2019 (COVID-19) Outbreak - an Update On the Status. Mil Med Res. 2020 03 13;7(1):11. PubMed PMID: 32169119.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. AU - Guo,Yan-Rong, AU - Cao,Qing-Dong, AU - Hong,Zhong-Si, AU - Tan,Yuan-Yang, AU - Chen,Shou-Deng, AU - Jin,Hong-Jun, AU - Tan,Kai-Sen, AU - Wang,De-Yun, AU - Yan,Yan, Y1 - 2020/03/13/ PY - 2020/02/29/received PY - 2020/03/09/accepted PY - 2020/3/15/entrez PY - 2020/3/15/pubmed PY - 2020/3/20/medline KW - Clinical characteristics KW - Coronavirus disease 2019 (COVID-19) KW - Origin KW - SARS-CoV-2 KW - Therapy KW - Transmission SP - 11 EP - 11 JF - Military Medical Research JO - Mil Med Res VL - 7 IS - 1 N2 - An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus. SN - 2054-9369 UR - https://www.unboundmedicine.com/medline/citation/32169119/The_origin_transmission_and_clinical_therapies_on_coronavirus_disease_2019__COVID_19__outbreak___an_update_on_the_status_ L2 - https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-00240-0 DB - PRIME DP - Unbound Medicine ER -